• GeoVax posted a Q2 net loss of $4.43 million, or $0.97 a share, narrowing from $5.37 million, or $8.74 a year earlier.
• Revenue was nil, versus $852,282 a year earlier after BARDA terminated the GEO-CM04S1 contract for convenience in April 2025.
• R&D expense fell to $3.11 million from $4.73 million on lower costs tied to discontinued BARDA work and reduced GEO-CM04S1 clinical spending.
• Cash was about $3.1 million at June 30, 2026, roughly flat versus Dec. 31, 2025.
• GeoVax expects to start its pivotal GEO-MVA immunobridging study in Q4 under an expedited EMA pathway, while advancing its Gedeptin immuno-oncology program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GeoVax Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-024522), on July 27, 2026, and is solely responsible for the information contained therein.